Ion AmpliSeq™ technology delivers simple and fast library construction for targeted sequencing of specific human genes or genomic regions. Based on ultrahigh-multiplex PCR, Ion AmpliSeq™ technology requires as little as 10 ng of input DNA or RNA per reaction to target sets of genes, including SNPs, CNVs, gene fusions, and indels, making sequencing of FFPE samples routine on the Ion PGM™ System.
Alternative target selection methods are lengthy and complex and require large amounts (hundreds of nanograms) of DNA, making them less practical for routine sequencing of DNA or RNA from the FFPE tissues commonly used in clinical cancer research, drug, and companion diagnostic development.
Because Ion AmpliSeq™ technology can amplify hundreds of biomarker targets in a single reaction, the Oncomine® Cancer Research Panel* can comprehensively analyze hundreds of the most referenced oncology biomarkers using just 3 primer pools. This not only enables a fast and easy workflow, but also helps ensure that important and actionable—but less prevalent—cancer variants are not missed.
With the power of Ion AmpliSeq™ technology, the Oncomine® Cancer Research Panel* could become your universal test for multiple oncology drug and companion diagnostic development programs.
Discuss the Oncomine® Cancer Research Panel* with a member of the clinical development team